A new class of 5‐HT2A/5‐HT2C receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2‐aminotetralins
Abstract
The 5‐HT receptor subtypes 5‐HT2A and 5‐HT2C are important neurotherapeutic targets, though, obtaining selectivity over 5‐HT2B and H1 receptors is challenging. Here, we delineated molecular determinants of selective binding to 5‐HT2A and 5‐HT2C receptors for novel 4‐phenyl‐2‐dimethylaminotetralins (4‐PATs).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 07, 2022
- Source ID
- 10.1111/bph.15756
Entities
People
- Austen B. Casey
- Meng Cui
- Munmun Mukherjee
- Raymond G. Booth
- Ryan P. McGlynn
- Stephen J. Kohut
Organizations
- Harvard Medical School
- National Institute on Drug Abuse
- Northeastern University
- United States Department of Defense